TORONTO and HAIFA, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce compelling new findings that highlight the therapeutic potential of ExoPTEN for patients with spinal cord injuries. In a recent preclinical study using a spinal cord compression model, our team demonstrated that ExoPTEN has a strong ability to target and accumulate at the injury site, even when administered up to one week after the injury occurred. This finding is crucial because it suggests a long window of time in which treatment can be effectively administered.
Dr. Lior Shaltiel, NurExone Chief Executive Officer, emphasized the real-world significance of this capability by stating that “the ability to treat patients up to 7 days post-injury could broaden the range of patients eligible for treatment and extend the window of effectiveness, leading to enhanced recovery. Moreover, the findings can enhance significantly the ability to recruit more patients to clinical trials and to expand the numbers of treatable patients, without being limited by a short therapeutic window and hospital administration challenges.” He continued, “With the global incidence of spinal cord injury estimated between 250,000 and 500,000i cases annually and given that some patients do not receive immediate treatment, the potential market for a therapy effective up to 1-week post-injury could be substantial.”